DE602008003404D1 - 5,6,7,8-tetrahydropteridin-derivate als hsp90-hemmer - Google Patents

5,6,7,8-tetrahydropteridin-derivate als hsp90-hemmer

Info

Publication number
DE602008003404D1
DE602008003404D1 DE602008003404T DE602008003404T DE602008003404D1 DE 602008003404 D1 DE602008003404 D1 DE 602008003404D1 DE 602008003404 T DE602008003404 T DE 602008003404T DE 602008003404 T DE602008003404 T DE 602008003404T DE 602008003404 D1 DE602008003404 D1 DE 602008003404D1
Authority
DE
Germany
Prior art keywords
hsp90 inhibitors
medicaments
treatment
tetrahydropteridine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602008003404T
Other languages
English (en)
Inventor
Thorsten Nowak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE602008003404D1 publication Critical patent/DE602008003404D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
DE602008003404T 2007-02-01 2008-01-31 5,6,7,8-tetrahydropteridin-derivate als hsp90-hemmer Active DE602008003404D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88771607P 2007-02-01 2007-02-01
US95065407P 2007-07-19 2007-07-19
PCT/GB2008/000303 WO2008093075A2 (en) 2007-02-01 2008-01-31 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors

Publications (1)

Publication Number Publication Date
DE602008003404D1 true DE602008003404D1 (de) 2010-12-23

Family

ID=39365852

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602008003404T Active DE602008003404D1 (de) 2007-02-01 2008-01-31 5,6,7,8-tetrahydropteridin-derivate als hsp90-hemmer

Country Status (13)

Country Link
US (1) US7799781B2 (de)
EP (1) EP2109612B1 (de)
JP (1) JP2010517989A (de)
KR (1) KR20090104920A (de)
CN (1) CN101652365A (de)
AT (1) ATE487720T1 (de)
AU (1) AU2008211729A1 (de)
BR (1) BRPI0807868A2 (de)
CA (1) CA2675677A1 (de)
DE (1) DE602008003404D1 (de)
MX (1) MX2009008084A (de)
RU (1) RU2009132605A (de)
WO (1) WO2008093075A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008061214A1 (de) * 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate
JP5565913B2 (ja) 2009-02-25 2014-08-06 第一三共株式会社 三環性ピラゾロピリミジン誘導体
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
BR112012006652A2 (pt) * 2009-09-25 2015-09-08 Vertex Pharma métodos para preparar os derivados de pirimidina úteis como inibidores de proteína cinase
TW201213333A (en) 2010-08-23 2012-04-01 Daiichi Sankyo Co Ltd Crystal forms of tricyclic pyrazolopyrimidine derivative
WO2012026433A1 (ja) 2010-08-23 2012-03-01 第一三共株式会社 三環性ピラゾロピリミジン誘導体のフリー体結晶
WO2012087943A2 (en) * 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
JP2015501793A (ja) 2011-11-10 2015-01-19 オーエスアイ・ファーマシューティカルズ，エルエルシー ジヒドロプテリジノン類
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
CA2961499A1 (en) 2014-09-17 2016-03-24 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
EP3468953B1 (de) 2016-06-13 2024-05-22 GlaxoSmithKline Intellectual Property Development Limited Substituierte pyridine als inhibitoren von dnmt1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177986B (en) * 1979-02-23 1982-02-28 Egyt Gyogyszervegyeszeti Gyar Process for preparing 1-acyl-1,2- or -1,4-dihydro-pyrido/3,4-e/-as-triazine derivatives
JP2000154139A (ja) 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd 縮環ピラジン誘導体
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
ATE225349T1 (de) 1998-11-12 2002-10-15 Neurocrine Biosciences Inc Crf rezeptor-antagonisten und darauf bezogene methoden
CN1501928A (zh) 2000-11-02 2004-06-02 斯隆-凯特林癌症研究所 结合hsp90的小分子组合物
US6806272B2 (en) * 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US7241890B2 (en) 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
EP1675861B1 (de) 2003-08-29 2015-12-23 Vernalis (R&D) Ltd. Pyrimidothiophenverbindungen
WO2005028434A2 (en) * 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
WO2006065703A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
MX2007011903A (es) 2005-03-30 2007-12-05 Conforma Therapeutics Corp Alquinil pirrolopirimidinas y analogos relacionados como inhibidores de hsp90.
WO2006117669A1 (en) 2005-05-03 2006-11-09 Pfizer Inc. Amide resorcinol compounds
DE102005022977A1 (de) 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
US20070105874A1 (en) 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
EP2012791A4 (de) * 2006-02-07 2010-09-22 Conforma Therapeutics Corp 7,9-dihydro-purin-8-on und analoge daraus als hsp90-hemmer
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative

Also Published As

Publication number Publication date
CN101652365A (zh) 2010-02-17
MX2009008084A (es) 2009-10-12
EP2109612A2 (de) 2009-10-21
ATE487720T1 (de) 2010-11-15
CA2675677A1 (en) 2008-08-07
RU2009132605A (ru) 2011-03-10
JP2010517989A (ja) 2010-05-27
AU2008211729A1 (en) 2008-08-07
US20080194572A1 (en) 2008-08-14
EP2109612B1 (de) 2010-11-10
BRPI0807868A2 (pt) 2013-10-15
KR20090104920A (ko) 2009-10-06
US7799781B2 (en) 2010-09-21
WO2008093075A3 (en) 2008-10-02
WO2008093075A2 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
MX2010014057A (es) Compuestos de piridina.
MX2009008953A (es) Compuestos como inhibidores de angiogenesis.
MX2009009843A (es) Compuestos espiro sustituidos como inhibidores de la angiogenesis.
MY150958A (en) Compounds for the treatment of multi-drug resistant bacterial infections
TR201904614T4 (tr) Novel pyrazole derivative.
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
TW200800998A (en) Phenylalanine derivatives
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
ATE520668T1 (de) Sigmarezeptor-inhibitoren
UA111588C2 (uk) Композиція інгібітора jak для місцевого застосування
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
AU2009282962A8 (en) Compounds as kinase inhibitors
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
EP2142549A4 (de) Adenosinderivate, verfahren zu deren synthese und pharmazeutische zusammensetzungen zur prävention und behandlung von entzündlichen krankheiten, die diese als wirkstoff enthalten
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
MX340985B (es) Compuestos de n-heteroarilo.
MX2008001211A (es) Derivados de bencilpiperazina y su uso medico.
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.